

| Catalog No. | HB058046 |
|---|---|
| Description |
Anti-Human CD142/F3/TF (MRG 004A) (HB058046) is a research-grade recombinant antibody targeting CD142. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | IgG |
| Clone ID | MRG 004A |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | Tissue factor, CD142, F3, Thromboplastin, Coagulation factor III, TF |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P13726 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | MRG-004A, MRG004A, MRG004A |
| Background | Tissue factor (CD142/F3) is a ~33 kDa protein. Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade. CD142 is the therapeutic target of tisotumab vedotin (Tivdak). |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD142/F3/TF (MRG 004A)




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский